|
|
A
rapid and systematic review of the effectiveness of temozolomide for the
treatment of recurrent malignant glioma
Dinnes J, Cave C, Huang S, Milne R
Southampton Health Technology Assessment Centre, Wessex Institute
for Health Research and Development, University of Southampton, Mailpoint 728,
Boldrewood, Southampton SO16 7PX, UK.
j.dinnes@soton.ac.uk.
A rapid and systematic review of the effectiveness and cost-effectiveness of
temozolomide in the treatment of recurrent malignant glioma was commissioned by
the NHS HTA Programme on behalf of NICE.
The full report has been published elsewhere.
This paper summarizes the results for the effectiveness of temozolomide in
people with recurrent glioblastoma multiforme and anaplastic astrocytoma.
The review was conducted using standard systematic review methodology involving
a systematic literature search, quality assessment of included studies with
systematic data extraction and data synthesis.
One randomized controlled trial and four uncontrolled studies were identified
for inclusion.
The key results were that temozolomide may increase progression-free survival
but has no significant impact on overall length of survival.
The main effect from temozolomide may have been in those patients who had not
received any prior chemotherapy regimens, however further randomized controlled
trials are required to confirm this suggestion.
Temozolomide appears to produce few serious adverse effects and may also have a
positive impact on health-related quality of life.
Overall the evidence-base is weak and few strong conclusions can be drawn
regarding the effectiveness of temozolomide.
Large, well-designed randomized controlled trails conducted in a wider patient
population are needed.
PMID:
11870527 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11870527&dopt=Abstract
|
